Preclinical feature articles

  1. Could Moving To This Swiss Life Sciences Hub Be In Your Company's Future? 1/15/2026

    Basel Area Business & Innovation CEO Christof Klöpper discusses how the Basel Area Life Sciences Supercluster supports discovery through commercialization.

  2. The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026 12/26/2025

    Antimicrobial resistance (AMR) has increasingly worried public health officials and researchers alike in 2025. Now, in 2026, TAXI Pharmaceutical President and CEO Gregory G. Mario, MBA, is calling for more targeted approaches and the integration of AI for quicker discovery and development.

  3. How The U.S. Can Beat China In Biotech 11/3/2025

    Lumen Bioscience's Brian Finrow breaks down China's biotech playbook and explores ways the U.S. can adapt it for its own continued success.

  4. How Redefining The Diagnostic Odyssey Can Lead To Better Patient Outcomes 10/22/2025

    Patient advocate Wendy Cogan calls for improved diagnostic pathways as a means to better clinical trial recruitment and design while telling the journey of her late husband's journey to a corticobasal degeneration(CBD)-frontal behavioral-spatial syndrome (FBS) diagnosis.

  5. Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development 10/21/2025

    Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.

  6. 100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing 10/17/2025

    Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.

  7. What Is Disease Progression Modeling, And When Is The Right Time To Use It? 10/16/2025

    With the help of Clinical Trials Transformation Initiative's Lindsay Kehoe, discover how disease progression modeling can improve trial efficiency, inform precision medicine, assist in regulatory decision-making, and more.

  8. How Enveric Biosciences Is Prepping For Its First IND 10/10/2025

    Enveric Biosciences CEO Joseph Tucker, Ph.D., discusses how the team is finalizing IND-enabling studies, leveraging both in-house expertise and trusted external partners.

  9. Oncology PI Shares Lessons Learned And Successes Working With Basic Scientists 10/9/2025

    Ranee Mehra, MD, shares her successes and discusses how they shape her approach to future research, as well as details the importance of working closely with basic scientists.

  10. Redesigning Oncology Trials Around Tumor Vulnerability: The Rise of WEE1 And DDR Strategies 9/8/2025

    As clinical progress with DNA damage response (DDR) continues to evolve, research must respond with adaptive models, smarter combinations, and biomarker-informed patient selection.